<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934
Date of Report: November 15, 2000
TITAN PHARMACEUTICALS, INC.
--------------------------
(Exact name of registrant as specified in charter)
DELAWARE
--------
(State or other jurisdiction of incorporation)
0-27436 94-3171940
----------- ----------
(Commission File Number) (IRS Employer Identification No.)
400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO, CALIFORNIA 94080
----------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (650) 244-4990
-------------
<PAGE>
Item 5. OTHER EVENTS
On November 15, 2000, the Registrant entered into definitive purchase
agreements for the sale of an aggregate of 1,200,000 shares of Common Stock
to institutional investors for net proceeds of approximately $41 million,
after deducting fees and commissions and other expenses of the offering (the
"Offering"). Deutsche Bank Securities, Inc./Deutsche Bank Alex. Brown acted
as placement agent for the transaction.
The Company has agreed to use its best efforts to file a registration
statement covering the resale of the shares under the Securities Act of 1933, as
amended, within 15 days after the closing of the transaction.
Reference is made to the related press release filed as Exhibit 20.1
hereto, which is incorporated by reference herein.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
20.1 Press Release dated November 16, 2000
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TITAN PHARMACEUTICALS, INC.
By: /s/ Sunil Bhonsle
---------------------------------
Sunil Bhonsle, Executive Vice
President and Chief Operating Officer
Dated: November 16, 2000
